Firm will also test the adenovector-based vaccine, which carries an antigen against Plasmodium vivax.

GenVec entered into a CRADA with the U.S. Military Malaria Vaccine Program for the development and preclinical testing of a malaria vaccine candidate against Plasmodium vivax (P. vivax). Partners include Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center.

In addition to the CRADA, GenVec has signed a one-year contract with the DoD to construct and test the adenovector-based vaccine, which carries a novel antigen against P. vivax developed by WRAIR scientists. GenVec and its collaborators will jointly design preclinical studies to evaluate the immunogenicity of the adenovector and WRAIR’s recombinant sub-unit vaccine in various combination prime/boost vaccination strategies.

Previous articleRegulus Therapeutics Spun Out of Isis and Alnylam to Focus on miRNA Drugs
Next articleRXi Pharmaceuticals Licenses RNA Chemistry Technologies from TriLink Biotechnologies